Abstract
BRCA1/2 mutations and poly (ADP-ribose) polymerase (PARP) inhibitors are paradigmatic of synthetic lethal therapy. However, the activity of PARP inhibitors seems to vary considerably across BRCA1/2-mutant cancers and new insights into the tumour-lineage dependency of this synthetic lethal relationship might explain why BRCA1/2 mutations are not tumour-agnostic biomarkers of a response to PARP inhibitors.
Original language | English |
---|---|
Pages (from-to) | 725–726 |
Journal | Nature Reviews Clinical Oncology |
Volume | 16 |
DOIs | |
Publication status | Published - 3 Oct 2019 |
Externally published | Yes |